111 related articles for article (PubMed ID: 24729271)
1. Population pharmacokinetics of hydroxyurea for children and adolescents with sickle cell disease.
Wiczling P; Liem RI; Panepinto JA; Garg U; Abdel-Rahman SM; Kearns GL; Neville KA
J Clin Pharmacol; 2014 Sep; 54(9):1016-22. PubMed ID: 24729271
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and bioequivalence of a liquid formulation of hydroxyurea in children with sickle cell anemia.
Estepp JH; Melloni C; Thornburg CD; Wiczling P; Rogers Z; Rothman JA; Green NS; Liem R; Brandow AM; Crary SE; Howard TH; Morris MH; Lewandowski A; Garg U; Jusko WJ; Neville KA;
J Clin Pharmacol; 2016 Mar; 56(3):298-306. PubMed ID: 26201504
[TBL] [Abstract][Full Text] [Related]
3. Development of a pharmacokinetic-guided dose individualization strategy for hydroxyurea treatment in children with sickle cell anaemia.
Dong M; McGann PT; Mizuno T; Ware RE; Vinks AA
Br J Clin Pharmacol; 2016 Apr; 81(4):742-52. PubMed ID: 26615061
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic profile of the anti-sickling hydroxyurea in wild-type and transgenic sickle cell mice.
Iyamu WE; Lian L; Asakura T
Chemotherapy; 2001; 47(4):270-8. PubMed ID: 11399864
[TBL] [Abstract][Full Text] [Related]
5. Hydroxycarbamide in children with sickle cell anaemia after first-dose vs. chronic therapy: pharmacokinetics and predictive models for drug exposure.
Estepp JH; Wiczling P; Moen J; Kang G; Mack JM; Liem R; Panepinto JA; Garg U; Kearns G; Neville KA
Br J Clin Pharmacol; 2018 Jul; 84(7):1478-1485. PubMed ID: 28884840
[TBL] [Abstract][Full Text] [Related]
6. Plasma and urine hydroxyurea levels might be useful in the management of adult sickle cell disease.
Bachir D; Hulin A; Huet E; Habibi A; Nzouakou R; El Mahrab M; Astier A; Galacteros F
Hemoglobin; 2007; 31(4):417-25. PubMed ID: 17994375
[TBL] [Abstract][Full Text] [Related]
7. Robust clinical and laboratory response to hydroxyurea using pharmacokinetically guided dosing for young children with sickle cell anemia.
McGann PT; Niss O; Dong M; Marahatta A; Howard TA; Mizuno T; Lane A; Kalfa TA; Malik P; Quinn CT; Ware RE; Vinks AA
Am J Hematol; 2019 Aug; 94(8):871-879. PubMed ID: 31106898
[TBL] [Abstract][Full Text] [Related]
8. The measurement of urinary hydroxyurea in sickle cell anaemia.
Dalton RN; Turner C; Dick M; Height SE; Awogbade M; Inusa B; Okpala I; O'Driscoll S; Thein SL; Rees DC
Br J Haematol; 2005 Jul; 130(1):138-44. PubMed ID: 15982356
[TBL] [Abstract][Full Text] [Related]
9. Impact of renal function on hydroxyurea exposure in sickle-cell disease patients.
Pressiat C; Rakotoson MG; Habibi A; Barau C; Arrouasse R; Galactéros F; Stehlé T; Audard V; Hulin A; Bartolucci P
Br J Clin Pharmacol; 2021 May; 87(5):2274-2285. PubMed ID: 33217005
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and pharmacodynamics of hydroxyurea.
Gwilt PR; Tracewell WG
Clin Pharmacokinet; 1998 May; 34(5):347-58. PubMed ID: 9592619
[TBL] [Abstract][Full Text] [Related]
11. Hydroxyurea therapy in sickle cell anemia patients aids to maintain oral fungal colonization balance.
Salvia AC; Figueiredo MS; Braga JA; Pereira DF; Brighenti FL; Koga-Ito CY
J Oral Pathol Med; 2013 Aug; 42(7):570-5. PubMed ID: 23278631
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetics and pharmacodynamics of hydroxyurea in sickle cell anemia patients, a basis for optimizing the dosing regimen.
Paule I; Sassi H; Habibi A; Pham KP; Bachir D; Galactéros F; Girard P; Hulin A; Tod M
Orphanet J Rare Dis; 2011 May; 6():30. PubMed ID: 21619673
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetics of hydroxyurea in cancer patients.
Tracewell WG; Trump DL; Vaughan WP; Smith DC; Gwilt PR
Cancer Chemother Pharmacol; 1995; 35(5):417-22. PubMed ID: 7850924
[TBL] [Abstract][Full Text] [Related]
14. A pilot study of electronic directly observed therapy to improve hydroxyurea adherence in pediatric patients with sickle-cell disease.
Creary SE; Gladwin MT; Byrne M; Hildesheim M; Krishnamurti L
Pediatr Blood Cancer; 2014 Jun; 61(6):1068-73. PubMed ID: 24436121
[TBL] [Abstract][Full Text] [Related]
15. A retrospective study to assess the utility of frequent laboratory monitoring of pediatric patients with sickle cell disease on hydroxyurea.
Nevin J; Myers L; Osunkwo I; Kanter J
J Pediatr Hematol Oncol; 2014 Apr; 36(3):e180-4. PubMed ID: 24072249
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of hydroxyurea 1,000 mg coated breakable tablets and 500 mg capsules in pediatric and adult patients with sickle cell disease.
de Montalembert M; Bachir D; Hulin A; Gimeno L; Mogenet A; Bresson JL; Macquin-Mavier I; Roudot-Thoraval F; Astier A; Galactéros F
Haematologica; 2006 Dec; 91(12):1685-8. PubMed ID: 17145606
[TBL] [Abstract][Full Text] [Related]
17. Use of hydroxyurea in children with sickle cell disease: what comes next?
Ohene-Frempong K; Smith-Whitley K
Semin Hematol; 1997 Jul; 34(3 Suppl 3):30-41. PubMed ID: 9317199
[TBL] [Abstract][Full Text] [Related]
18. Low fixed-dose hydroxyurea in severely affected Indian children with sickle cell disease.
Jain DL; Sarathi V; Desai S; Bhatnagar M; Lodha A
Hemoglobin; 2012; 36(4):323-32. PubMed ID: 22734586
[TBL] [Abstract][Full Text] [Related]
19. Optimizing Hydroxyurea use in children with sickle cell disease: low dose regimen is effective.
Sharef SW; Al-Hajri M; Beshlawi I; Al-Shahrabally A; Elshinawy M; Zachariah M; Mevada ST; Bashir W; Rawas A; Taqi A; Al-Lamki Z; Wali Y
Eur J Haematol; 2013 Jun; 90(6):519-24. PubMed ID: 23489171
[TBL] [Abstract][Full Text] [Related]
20. Organic anion transporting polypeptide 1B transporters modulate hydroxyurea pharmacokinetics.
Walker AL; Lancaster CS; Finkelstein D; Ware RE; Sparreboom A
Am J Physiol Cell Physiol; 2013 Dec; 305(12):C1223-9. PubMed ID: 23986199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
